Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
The iShares Dow Jones US Healthcare (ETF) (NYSE:IYH) is up marginally year-to-date, but the profits aren’t bleeding into all health care constituents.
The Ratings
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Goldman Sachs analyst Jami Rubin upgraded Johnson & Johnson (NYSE:JNJ) from Sell to Neutral and maintained a $134 price target. Rubin downgraded Perrigo Company PLC (NYSE:PRGO) from Neutral to Sell and cut the price target from $78 to $74.
The Thesis
Rubin had been bearish on Johnson & Johnson only for its valuation, which she considered unjustly high relative to peers and given its poor earnings growth. As the stock now trades comparably with the group, it’s earned an upgrade, the analyst said in a Thursday note. (See Rubin's track record here.)
Goldman’s steady price target reflects pharma’s outperformance as well as durability in both consumer products and medical devices and diagnostics.
Perrigo’s downgrade is similarly justified by relative peer performance, Rubin said.
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
“We see no meaningful risk to numbers but expect the business to drift due to a lack of meaningful new launches in the pipeline,” the analyst said, referencing developments by Teva Pharmaceutical Industries Ltd (ADR) ADR (NYSE:TEVA) and Mylan NV (NASDAQ:MYL).
Perrigo's stabilizing prescription business is not seen to lend meaningful upside.
“Now consumer [over-the-counter] drives 75 percent of PRGO’s operating profits, and this industry is facing headwinds that we do not expect to abate anytime soon."
Price Action
Perrigo was trading down 1.94 percent at $76.25 at the time of publication, while Johnson & Johnson was up 1.05 percent at $127.56.
Related Links:
Analyst: Despite Industry Woes, Investigations, And Management Shake-Up, Perrigo Is A Buy
Analyst: Morphosys Is Well-Positioned To Continue Success With Antibody Discovery Platforms
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.